Follow
Sharvari Bhagwat
Sharvari Bhagwat
Scientist, Amgen
Verified email at amgen.com
Title
Cited by
Cited by
Year
Evaluation of the transwell system for characterization of dissolution behavior of inhalation drugs: effects of membrane and surfactant
M Rohrschneider, S Bhagwat, R Krampe, V Michler, J Breitkreutz, ...
Molecular pharmaceutics 12 (8), 2618-2624, 2015
812015
Predicting Pulmonary Pharmacokinetics from In Vitro Properties of Dry Powder Inhalers
S Bhagwat, U Schilling, MJ Chen, X Wei, R Delvadia, M Absar, B Saluja, ...
Pharmaceutical research 34, 2541-2556, 2017
502017
Optimization of the Transwell® System for Assessing the Dissolution Behavior of Orally Inhaled Drug Products through In Vitro and In Silico Approaches
E Amini, A Kurumaddali, S Bhagwat, SM Berger, G Hochhaus
Pharmaceutics 13 (8), 1109, 2021
92021
Development of an in vitro test method for dissolution of inhaled corticosteroids
S Bhagwat, M Rohrschneider, S Alfadehl, G Hochhaus
JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY 26 (2), A58-A59, 2013
52013
Characterization of clinical pharmacokinetics and exposure-response relationships of AMG 330, a bispecific CD33 T-cell engager antibody construct, in patients with relapsed …
SK Agarwal, S Bhagwat, K Mehta, A Hindoyan, AS Stein, F Ravandi, ...
Journal of Clinical Oncology 38 (15_suppl), 7536-7536, 2020
22020
Mechanistic pharmacokinetic/pharmacodynamic modeling in support of a patient-convenient, longer dosing interval for carfilzomib, a covalent inhibitor of the proteasome
MR Yago, K Mehta, M Bose, S Bhagwat, VS Chopra, S Dutta, VV Upreti
Clinical Pharmacokinetics 62 (5), 779-788, 2023
12023
Recombinant Human Alpha-1 Antitrypsin (AAT) Protein INBRX-101 Demonstrates Potential to Achieve Lung Penetration and Normal Functional Serum AAT Levels in Patients With AAT …
BT Kuhn, A Veale, H Farah, R Mahadeva, CL Chang, CD Brown, ...
C15. EMERGING COPD DIAGNOSTICS AND TREATMENTS, A4492-A4492, 2023
12023
Evaluation of Safety and Pharmacokinetics of the Recombinant Human AAT-Fc Fusion Protein INBRX-101 in Patients with Alpha-1 Antitrypsin Deficiency
A Veale, J Kalabus, H Farah, R Mahadeva, BT Kuhn, A Cole, CL Chang, ...
C41. ALPHA-1 ANTITRYPSIN DEFICIENCY, A4114-A4114, 2022
12022
ACCURATE PREDICTION OF CLINICAL PHARMACOKINETICS OF THREE GENERATIONS OF BISPECIFIC T-CELL ENGAGERS (CANONICAL BITE CONSTRUCT; HALF-LIFE EXTENDED BITE CONSTRUCT; BISPECIFIC …
V Upreti, M Yago, J Kast, D Zhou, H Wong, S Dhuria, S Agarwal, ...
CLINICAL PHARMACOLOGY & THERAPEUTICS 109, S56-S56, 2021
12021
Effective dosage of recombinant serpin-fc fusion protein for use in a method of treating aat deficiency in a subject
J Kalabus, S Bhagwat
US Patent App. 18/318,425, 2023
2023
Recombinant AAT-Fc fusion protein INBRX-101 achieves normal serum AAT levels in patients with alpha-1 antitrypsin deficiency (AATD)
A Veale, H Farah, R Mahadeva, M Baker, B Kuhn, A Cole, C Chang, ...
European Respiratory Journal 60 (suppl 66), 2022
2022
INBRX-101: A Novel Recombinant AAT-Fc Fusion Protein That Achieves Normal Serum AAT Levels with Extended Interval Dosing for Patients with Alpha-1 Antitrypsin Deficiency
A Veale, J Kalabus, H Farah, R Mahadeva, BT Kuhn, A Cole, CL Chang, ...
B14. OLD DOGS NEW TRICKS: LATE-BREAKING ABSTRACTS IN OBSTRUCTIVE LUNG …, 2022
2022
Systematic Evaluation of the Effect of Formulation Variables on In Vitro Performance of Mometasone Furoate Suspension-Metered Dose Inhalers
SS Bachhav, P Sheth, D Sandell, M Svensson, S Bhagwat, DS Conti, ...
The AAPS journal 24 (1), 9, 2021
2021
MECHANISTIC PK/PD MODELING IN SUPPORT OF A PATIENT-CONVENIENT, ONCE-WEEKLY DOSING REGIMEN OF KYPROLIS (CARFILZOMIB).
M Yago, S Bhagwat, K Mehta, Z Klippel, M Obreja, V Chopra, S Dutta, ...
CLINICAL PHARMACOLOGY & THERAPEUTICS 107, S73-S73, 2020
2020
2017 Annual Meeting-What you need to know before you arrive
J Ahn, S Albusaysi, J Alfonsi, A Ande, P Bank, E Barr, J Bezencon, ...
CLINICAL PHARMACOLOGY & THERAPEUTICS 101 (3), 310-316, 2017
2017
Dissolution testing - Exploring the link between particle size and dissolution behavior for OINDPs
Kippax P., Huck-Jones D., Suman J., Hochhaus G.,Bhagwat S.
Drug Development and Delivery, 2016
2016
Recombinant Human AAT Protein INBRX-101 Demonstrates Potential to Achieve Lung Penetration and Normal Functional Serum AAT Levels in Patients With AAT Deficiency
BT Kuhn, A Veale, H Farah, R Mahadeva, CL Chang, CD Brown, ...
History 2, 6.5, 0
The system can't perform the operation now. Try again later.
Articles 1–17